PhaseBio Pharmaceuticals' Series D Round

PhaseBio Pharmaceuticals raised a round of funding on September 05, 2018.

PhaseBio Pharmaceuticals (PHAS) is a clinical-stage biopharmaceutical company developing drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's …

Articles about PhaseBio Pharmaceuticals' Series D Round: